AstraZeneca shares oversold after trial flops and merger talk, says UBS

{
  "signal_id": "1371a883-ce57-a667-45b6-5286a2e14a5f",
  "signal_type": "news",
  "signal_subtype": "invests_into_assets",
  "detected_at": "2026-09-16T14:41:03+00:00",
  "company": {
    "name": "AstraZeneca",
    "domain": "astrazeneca.com"
  },
  "data": {
    "url": "https://www.proactiveinvestors.com/companies/news/1098628/astrazeneca-shares-oversold-after-trial-flops-and-merger-talk-says-ubs-1098628.html",
    "title": "AstraZeneca shares oversold after trial flops and merger talk, says UBS - Proactive financial news",
    "assets": "factories",
    "excerpt": "Ian Lyall, a seasoned journalist and editor, brings over three decades of experience to his role as Managing Editor at Proactive. Overseeing Proactive's editorial and broadcast operations across six offices on three continents, Ian is responsible for quality control, editorial policy, and content production. He directs the creation of 50,000 pieces of real-time news, feature articles, and filmed interviews annually. Prior to Proactive, Ian helped lead the business output at the Daily... Read more Proactive financial news and online broadcast teams provide fast, accessible, informative and actionable business and finance news content to a global investment audience. All our content is produced independently by our experienced and qualified teams of news journalists. Proactive news team spans the world’s key finance and investing hubs with bureaus and studios in London, New York, Toronto, Vancouver, Sydney and Perth. We are experts in medium and small-cap markets, we also keep our community up to date with blue-chip companies, commodities and broader investment stories. This is content that excites and engages motivated private investors. The team delivers news and unique insights across the market including but not confined to: biotech and pharma, mining and natural resources, battery metals, oil and gas, crypto and emerging digital and EV technologies. Proactive has always...",
    "summary": "AstraZeneca has recently invested $15 billion in China to support its ambition of reaching $80 billion in revenue.",
    "location": "China",
    "planning": false,
    "image_url": "https://cdn.proactiveinvestors.com/eyJidWNrZXQiOiJwYS1jZG4iLCJrZXkiOiJ1cGxvYWRcL05ld3NcL0ltYWdlXC8yMDI2XzA5XC9Bc3RyYTMuanBnIiwiZWRpdHMiOnsicmVzaXplIjp7IndpZHRoIjoxMjAwLCJoZWlnaHQiOjYzMCwiZml0IjoiY292ZXIifX19",
    "confidence": 0.9,
    "assets_tags": [
      "production"
    ],
    "published_at": "2026-09-16T14:41:03Z",
    "location_data": [
      {
        "region": "Eastern Asia",
        "country": "China",
        "continent": "Asia",
        "fuzzy_match": false
      }
    ],
    "article_sentence": "Cheng said the company's factories can support the $80 billion ambition, backed by recent investments of $50 billion in the United States, $15 billion in China and $1.5 billion in Singapore.",
    "amount_normalized": 15000000000
  }
}

curl https://signals.autobound.ai/v1/signals/1371a883-ce57-a667-45b6-5286a2e14a5f \
  -H "X-API-KEY: $AUTOBOUND_API_KEY"

curl -X POST https://signals.autobound.ai/v1/companies/enrich \
  -H "X-API-KEY: $AUTOBOUND_API_KEY" \
  -H "Content-Type: application/json" \
  -d '{"domain":"astrazeneca.com","limit":20}'